# Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

> **NCT07694674** · — · RECRUITING · sponsor: **Shanghai 10th People's Hospital** · enrollment: 198 (estimated)

## Conditions studied

- Inflamatory Bowel Disease
- Crohn Disease (CD)

## Interventions

- **BIOLOGICAL:** Infliximab
- **BIOLOGICAL:** Adalimumab
- **BIOLOGICAL:** Vedolizumab
- **BIOLOGICAL:** Ustekinumab (UST)

## Key facts

- **NCT ID:** NCT07694674
- **Lead sponsor:** Shanghai 10th People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694674, "Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*